Erectile dysfunction (ED) is a prevalent complication associated with diabetes mellitus (DM), yet pharmacological treatments for diabetes-related erectile dysfunction (DMED) continue to be inadequate in clinical settings. Our previous studies have indicated that there is a close correlation between ED and pyroptosis, but the specific mechanism remains unclear. In this study, we sought to explore the therapeutic effects of DMED through the modulation of NLRP3, aiming to elucidate its potential molecular mechanisms. The DMED rat model was established via intraperitoneal injection of streptozotocin. The rats were randomly assigned to the control group, the DMED group, the Yimusake group, the MCC950 (NLRP3 inhibitor) group, and the MCC950+Yimusake group. Erectile function of rats was observed by measuring intracavernosal pressure (ICP) and mean arterial pressure (MAP). HE staining was performed to observe the histopathological changes in penile; immunofluorescence was performed to measure the level of CD31 (Platelet endothelial cell adhesion molecule-1) in penile. Besides, immunohistochemistry, RT-qPCR and Western blot were performed to demonstrate the expression of NLRP3, caspase-1, IL-1β and eNOS. After treatment with the MCC950 and Yimusake, the number of blood sinusoids and small vessels significantly reduced in penile tissue; NLRP3, caspase-1, IL-1β proteins and mRNA expression decreased, eNOS protein and mRNA expression increased. Compare with the Y group and the MCC950 group, MCC950+Yimusake group had a more significant effect. MCC950 and Yimusake might potentially suppress pyroptosis in the penile tissue of DMED rats by modulating the NLRP3/caspase-1 pathway, thus enhancing erectile function. This discovery could offer a promising therapeutic approach for individuals with DMED.

2020-02-01·Zhonghua nan ke xue = National journal of andrology

[Regulatory effect of the lipid metabolic pathways of TMAO, FMO3 and FXR on compound stress-induced ED in rats and mechanisms of Yimusake intervention].

Article

作者: Liu, Wen-Juan ; Yuan, Qian-Ru ; Siyiti, Amuti ; Aizizi, Reheman ; Adlijiang, Yiming ; Tian, Yan-Nan ; Liu, Feng-Xia

OBJECTIVETo study of the regulatory effects of the lipid metabolic pathways of trimethylamine-N-oxide (TMAO), flavin-containingmonooxidase 3 (FMO3) and farnesoid X receptor (FXR) on compound stress-induced ED (CSED) rats and the mechanisms of Yimusake Tablets (YMSK) intervention.METHODSBased on the results of metabonomics analysis, we determined the concentration of TMAO in the serum of the rats in the normal control (n = 30), the CSED model control (n = 30) and the YMSK intervention group (intragastrical administration of YMSK at 250 mg/kg once daily for 2－3 weeks after modeling, n = 30) by nuclear magnetic resonance (NMR) spectroscopy test. We also detected the expressions of the FMO3, FXR1 and FXR2 proteins in the liver tissue of the three groups of rats by Western blot.RESULTSThe serum TMAO level was significantly elevated in the CSED model control compared with that in the normal control group (［46.64 ± 5.16］ vs ［34.98 ± 3.69］ μg/mL, P < 0.01) but remarkably decreased after YMSK intervention (［39.63 ± 4.81］ μg/mL) in comparison with that in the CSED model control group (P < 0.01). The rats in the CSED model control group, compared with the normal controls, showed significantly upregulated expressions of FMO3 (1.75 ± 0.90 vs 0.86 ± 0.62, P < 0.01),FXR1 (1.29 ± 0.38 vs 0.78 ± 0.25, P < 0.01) and FXR2 in the liver tissue (1.90 ± 0.63 vs 0.42 ± 0.27, P < 0.01), but all the three expressions were markedly decreased after YMSK intervention (FMO3: 1.05 ± 0.38, P < 0.05; FXR1: 1.07 ± 0.42, P < 0.05; FXR2: 1.04 ± 0.46, P < 0.01) as compared with those in the CSED model control group.CONCLUSIONSThe lipid metabolic pathways of TMAO, FMO3 and FXR underwent significant changes in the rat model of compound stress-induced ED, which could be improved by YMSK intervention, suggesting that YMSK may play an important role in protecting erectile function by regulating the lipid metabolic pathways of TMAO, FMO3 and FXR.

2019-12-01·Zhonghua nan ke xue = National journal of andrology

[Differentially expressed proteins in the penile tissue of rats with compound stress-induced ED after intervention with Yimusake Tablets: A bioinformatics analysis].

Article

作者: Xieraili, Maimaiti ; Adilijiang, Yiming ; Siyiti, Amuti ; Liu, Wen-Juan ; Ma, Wen-Jing ; Zhang, Pan-Pan ; Maowulan, Maimaitiyiming

OBJECTIVETo search for specific protein makers and target proteins for intervention with Yimusake Tablets (YT) in the penile tissue of rats with ED induced by compound cold stress and explore the molecular mechanisms underlying the development and progression of ED.METHODSEighty adult male rats were screened and divided into three groups, normal control (n = 10), ED model control (n = 15) and YT intervention (n = 15). The model of compound cold stress-induced ED was established in the latter two groups, and meanwhile the animals in the YT intervention group were treated with oral YT for 2 weeks. After that, proteins were extracted from the penile tissues of the rats for screening and identification by iTRAQ labeling combined with LC-MS-MS proteomics, and the IPA bioinformatics software was used for analysis of differentially expressed proteins.RESULTSA total of 48 differentially expressed proteins were identified from the penile tissue of the ED model controls, of which 18 were associated with endothelial function, 5 with smooth muscle activity and 4 with inflammation, involving the biological processes of glucose metabolism and alcohol catabolism and the signaling pathways of glucose metabolism, calcium and RXR activation. In comparison, 29 differentially expressed proteins were identified from the rats in the YT intervention group, of which 5 were associated with endothelial function, 1 with smooth muscle activity and 4 with inflammation, involving the biological processes of glucose metabolism, vasodilation and acute-phase response and the signaling pathways glucose metabolism, RXR activation and acute-phase response. Seven ED-associated candidate biomarkers were obtained from the differentially expressed proteins in the ED model control and YT intervention group, including Collagen alpha-1(III) chain（COL3α1）, Collagen alpha-1(I) chain（COL1α1）, Collagen alpha-2(I) chain（COL1α2）, Glyceraldehyde-3-phosphate dehydrogenase（GAPDH）, T-kininogen 1（MAP1）,Biglycan（BGN）, and Myosin-11（MYH11）.CONCLUSIONSChanges of vascular endothelial and smooth muscle functions in the penile tissue are likely to be the key mechanisms underlying the development and progression of compound stress-induced ED, which is also associated with inflammation as well as the interaction of the identified differentially expressed proteins and their participation in the relevant signaling pathways. The 7 proteins obtained can be used as the markers of compound stress-induced ED in the rat penile tissue, of which MAP1, GAPDH, BGN and MYH11 may serve as target proteins for YT intervention.

项与伊木萨克相关的新闻（医药）

2024-08-20

·药融云

35个药品主动降价！亿级“独家”品种降幅微小……

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 8月16日，辽宁省药品集中采购网发布一则药品降价通知，于08月21日起执行新的挂网采购价格。本次共有35个药品主动调价，降价产品设置采购过渡期，时间为1周。 35个药品主动降价，涵盖了化学药、中成药两大类，其中化学药占比超7成。在剂型方面，本次注射剂占比超50%，从治疗领域大类来看，呼吸系统药物占比最高，达20%，其次是神经系统药物和心血管系统药物，均占比超17%。 35个药品主动降价名单（标红为独家）数据来源：辽宁省药品集中采购网、药融云整理从降价幅度来看，其中，氨基己酸注射液由119.9元下降至30.17元，降幅74.84%，是本次降幅最大的药品。此外，双石通淋胶囊由44.93元下降至44.92元，降幅0.02%，是本次降幅最小的药品。双石通淋胶囊是陕西摩美得气血和制药的独家中成药品品种，主要是清热利尿，化浊通淋。用于慢性前列腺炎湿热壅阻证。症见尿道灼热、小便频急、尿后余沥不尽、尿后滴白、阴部潮湿、会阴、少腹、腰骶部疼痛或不适，舌质红苔黄，脉弦或弦滑等。据药融云数据库显示，双石通淋胶囊在2023年全国院内市场的销售额超1亿元，同比增长达21.35%。截图来源：药融云全国医院销售数据库此外，35个主动降价的药品中，有11个产品降幅均低于10%，涉及上海旭东海普药业的氢溴酸加兰他敏注射液、国药集团国瑞药业的阿加曲班注射液、北京百奥药业的二甲双胍恩格列净片(Ⅰ)等此次35个主动降价的药品中有3个独家中成药，涉及四川宝兴制药的独家中成药品种加味逍遥片、和田维吾尔药业的独家中成药品种伊木萨克片、陕西摩美得气血和制药的独家中成药品种双石通淋胶囊。 END 本文为原创文章，转载请留言获取授权近期热门资源获取后台回复关键词“报告”，获取数十篇药融云出品独家报告后台回复关键词“CSCO”，获取2023CSCO指南后台回复关键词“ASCO”，获取2023ASCO分癌种摘要后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复关键词“医保”，获取2022年医保目录联系我们，体验药融云更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，申请药融云企业版免费试用！

ASCO会议CSCO会议带量采购

100 项与伊木萨克相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
神经衰弱	中国	新疆维吾尔自治区维吾尔医医院	1999-01-01
泌尿生殖系统疾病	中国	新疆维吾尔自治区维吾尔医医院	1999-01-01